7C225672-8372-4202-A749-3D8E9A0747CC
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 11.268068331143231
- age_years
- 44
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.385
- NOTCH_SIGNALING+0.369
- WNT_BETA_CATENIN_SIGNALING+0.327
- TGF_BETA_SIGNALING+0.258
- HEDGEHOG_SIGNALING+0.200
- G2M_CHECKPOINT+0.176
- CHOLESTEROL_HOMEOSTASIS+0.134
- MYC_TARGETS_V2+0.112
- DNA_REPAIR+0.111
- PROTEIN_SECRETION+0.106
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.402
- ALLOGRAFT_REJECTION-0.369
- KRAS_SIGNALING_DN-0.347
- OXIDATIVE_PHOSPHORYLATION-0.345
- IL6_JAK_STAT3_SIGNALING-0.329
- HYPOXIA-0.323
- INTERFERON_GAMMA_RESPONSE-0.320
- INFLAMMATORY_RESPONSE-0.299
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.294
- COAGULATION-0.253
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | A130FABA-F55F-412D-940E-7305057B4D1A | — | — | 0.887 |
| 2 | SRR934728 | — | — | 0.883 |
| 3 | MNG522 | — | — | 0.841 |
| 4 | 4549956C-8D25-4B37-894C-E82D5C7684F0 | — | — | 0.838 |
| 5 | 589A94F8-2432-4D6D-94EB-B327ECA291AF | — | — | 0.824 |
| 6 | 4FC69960-8EF2-49FE-A718-7004E99E00A8 | — | — | 0.823 |
| 7 | 507DED46-D79C-4A9F-BCF9-22E9C2CFD334 | — | — | 0.817 |
| 8 | SRR934951 | — | — | 0.816 |
| 9 | SRR934847 | — | — | 0.808 |
| 10 | 2CB84056-3B7C-4E12-9403-596B76CCF96B | — | — | 0.805 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.385 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.369 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.327 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.258 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.176 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.134 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.112 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.111 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.106 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.089 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.062 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.053 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.041 | Inavolisib | — uncovered |
| PEROXISOME | 0.029 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.023 | Inavolisib | — uncovered |